An interventional study of Tele-neurohub in Lewy Body Dementia With Behavioral Disturbance, Lewy Body Parkinson Disease and Lewy Body Disease, sponsored by University of Florida. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University of Florida · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Parkinson Disease by University of Florida — 5 open to participants now, 6 under way, none of them phase 3. Parkinson Disease · University of Florida.
Among the 41 studies in Parkinson Disease by University of Florida, this one is the 10th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2022, is one of 25 with no phase, and was the 31st registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →5 of the 41 studies in Parkinson Disease by University of Florida are open now, in 1 country. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 40–75
University of Florida · Sites in United States
Ages 18–80
University of Florida · Sites in United States
Ages 21–89
University of Florida · Sites in United States
Ages 18–80
University of Florida · Sites in United States
Ages 45–85
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 35 across the 33 interventional studies, 30 across the 8 observational. Of the 34 that completed or were terminated, 9 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
3 of the studies in Parkinson Disease by University of Florida that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07348705University of FloridaElectrophysiology-based DBS Programming for PD | 2027-01-15 |
| NCT05913687University of FloridaAutomated Imaging Differentiation of Parkinsonism | 2027-03-31 |
| NCT06911229University of FloridaNeurophysiology of Locomotor Adaptation and Freezing of Gait in Parkinson's Disease | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 41 studies in Parkinson Disease by University of Florida, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lewy body dementia (LBD) is the 2nd most common neurodegenerative dementia in the US. Optimal care requires an interdisciplinary approach, however often faced barriers include rural residence, limited access to specialists, travel distance, limited awareness of resources, and physical, cognitive, and behavioral impairments making travel to appointments challenging. Delivering interdisciplinary care remotely using video technology has the potential to improve access to care for patients with LBD.
The purpose of this study is to convert an in-person patient-centric interdisciplinary care model to a virtual platform using stakeholder engagement from individuals with LBD, their caregivers and healthcare providers. Subsequently researchers will conduct a prospective, randomized, controlled pilot study implementing the virtual stakeholder developed interdisciplinary care model (tele-neurohub) for 6 month and assess the implementation outcomes of feasibility, acceptability, and appropriateness of the tele-neurohub model. The research goal is to establish and iteratively improve a virtual interdisciplinary model of care allowing patients with LBD and their caregivers to access sub-specialty care from their home.
Participant with Lewy Body Dementia (LBD) Inclusion Criteria:
This group will receive the tele-neurohub intervention which includes telemedicine appointments with the neurologist, speech therapist, social worker, and nutritionist at baseline, 3 months and 6 months, and PT and OT every 2 weeks for maintenance neuro-rehabilitation.
Behavioral: Tele-neurohub
Receive usual care but will have study visit assessments at baseline and 6 months.
Behavioral: Tele-neurohub
Interdisciplinary care delivered using telemedicine (zoom) technology which includes neurologist, physical, occupational and speech therapy, social worker and dietician.
Number of completed tele-health visits
Feasibility will be determined by completion of at least 75% telehealth visits by the intervention cohort
Time frame: 6 months
Satisfaction assessed by Patient Assessment of Communication of Telehealth questionnaire.
Acceptability will be determined by at least 80% of dyads reporting being "satisfied" or "highly satisfied" on the Patient Assessment of Communication of Telehealth questionnaire.
Time frame: 6 months
Appropriateness assessed by Intervention Appropriateness Measure
Appropriateness will be determined by the Intervention Appropriateness Measure, higher scores indicate greater appropriateness
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2022 to primary completion in Nov 2026, 56 months.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 56 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.